2024
Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder
Farhat L, Flores J, Avila-Quintero V, Polanczyk G, Cipriani A, Furukawa T, Bloch M, Cortese S. Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry 2024, 81: 157-166. PMID: 37878348, PMCID: PMC10600727, DOI: 10.1001/jamapsychiatry.2023.3985.Peer-Reviewed Original ResearchAttention-deficit/hyperactivity disorderLicensed dosesDose-response curveStimulant dosesClinical trialsTreatment outcomesRisk benefitHyperactivity disorderReduction of symptomsDrug Administration recommendationsAdverse eventsDose escalationLanguage restrictionsAdministration recommendationsUS FoodSymptomsDosesAdditional riskData extractionAdditional reductionADHD symptomsAdultsGreater reductionStimulantsRisk
2022
The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis
Farhat LC, Flores JM, Behling E, Avila-Quintero VJ, Lombroso A, Cortese S, Polanczyk GV, Bloch MH. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molecular Psychiatry 2022, 27: 1562-1572. PMID: 35027679, DOI: 10.1038/s41380-021-01391-9.Peer-Reviewed Original ResearchConceptsFixed-dose trialAttention-deficit/hyperactivity disorderDose-limiting adverse eventsChildren/adolescentsAdverse eventsFlexible-dose trialTerms of efficacyClinical practiceHigh dosesFlexible dose designIntolerable adverse eventsHyperactivity disorderIncremental benefitLikelihood of discontinuationADHD symptomsLarge systematic reviewSchool-aged children/adolescentsFlexible titrationPotential long-term effectsSymptom controlTreatment discontinuationClinical outcomesStimulant dosesDaily dosesClinical guidelines